RBD 1073
Alternative Names: RBD-1073Latest Information Update: 30 Aug 2023
At a glance
- Originator Suzhou Ribo Life Science
- Class Amino sugars; Drug conjugates; Hepatoprotectants; Small interfering RNA
- Mechanism of Action 17-hydroxysteroid dehydrogenase modulators; RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Non-alcoholic steatohepatitis
Most Recent Events
- 19 Jul 2023 RBD 1073 is available for licensing as of 19 Jul 2023. https://www.ribolia.com/En/bd-and-collaboration
- 19 Jul 2023 Preclinical trials in Non-alcoholic steatohepatitis in China (unspecified route) (Suzhou Ribo Life Science pipeline, July 2023)
- 31 May 2023 Suzhou Ribo Life Science has patent protection for small RNAi technologies in China (Suzhou Ribo Life Science pipeline, July 2023)